玻璃体腔注射抗VEGF药物治疗早产儿视网膜病变的研究进展

早产儿视网膜病变(ROP)是发生于早产儿的一种未成熟视网膜血管增殖性眼病，是一种严重的儿童致盲性眼病。视网膜激光光凝术是治疗ROP的经典方法，然而激光治疗是破坏性的，尤其是在ROP Ⅰ区病变的情况下，视网膜激光光凝治疗会引起严重的并发症。研究表明，血管内皮细胞生长因子(VEGF)在ROP发生及发展过程中具有关键作用，而玻璃体腔注射抗VEGF药物不仅能有效控制ROP，并且为视网膜继续发育争取了机会。本文就玻璃体腔内注射抗VEGF药物治疗ROP的治疗指征、药物筛选、注射部位、给药剂量、疗效观察以及并发症对其进行综述。

Anti-VEGF therapy in retinopathy of prematurity

Retinopathy of prematurity(ROP)is an immature proliferative retinal vascular disease that may lead to permanent blindness in preterm infant. Retinal laser photocoagulation is used for ablation of peripheral retina and treatment of ROP, however, it is destructive. Especially for the cases with lesions in Zone I region, retinal laser photocoagulation may cause severe complications. Recently, studies have demonstrated that vascular endothelial growth factor(VEGF)plays a causal role in the pathogenesis of ROP, and intravitreal injection of anti-VEGF agents can not only effectively impede ROP progression, but also gain timing for revascularization of a vascular retinal region. This article reviews the treatment indications, drug selection, injection site, dosage recommendation, follow-up of efficacy and complications of intravitreal injection of anti-VEGF agents in the treatment of ROP.